Blood Test May Reveal Features Of Metastatic Cancer – Nation World News


In the future, doctors will make better decisions about managing a patient’s cancer.

Blood-based biopsy techniques have become a tool for clinical genotyping of cancer. Photo: Shutterstock.

A new report suggests that an analysis of sangre The deoxyribonucleic acid (DNA) shed by metastatic tumors can reveal the unique characteristics of each patient’s tumor and allow specialists to develop personalized treatments.

analysis of sangre Circulating tumor DNA (ctDNA) is concentrated. By sequencing its entire genome, researchers can learn about the various metastases spread throughout the body.

In this regard, the study’s senior author, Alexander Wyatt, MD, D. Phil., assistant professor of genomics cancer A senior research scientist at the University of British Columbia’s Genital Research and Vancouver Prostate Center said that “a major goal in the research of cancer to better understand cancer metastatic in each affected person so that we can choose the best treatments and avoid giving toxic treatments to those who will not benefit.

Despite this, the specialist indicated that the biopsy cancer metastatic Because they are invasive and there are risks of complications. Years ago, this barrier prevented extensive study of cancer metastatic And moving towards better treatment of this deadly disease.

based on biopsy techniques sangreAlso known as “liquid biopsy”, has become a tool for diagnostic genotyping cancer and longitudinal monitoring of disease.

The study’s authors noted that trials using circulating tumor DNA have begun to affect people’s clinical management of cancerAlthough the full ability to understand biology cancer metastatic,

Dr. Wyatt and colleagues analyzed serial plasma and synchronous metastases patients Thief cancer Treatment-resistant prostate cancer through intensive whole-genome sequencing, which enables comprehensive evaluation of each part of the genetic code within cancer cells.

The researchers evaluated all classes of genomic alterations and found that circulating tumor DNA contained several major populations, indicating that most people cancer metastatic They have individual metastases spread throughout their bodies. They found that the whole genome sequencing process provides a wealth of information about these different metastases.

The research team used newly developed computer programs to provide information about the genetic makeup of each population. cancerwhich can tell researchers about a person’s overall disease rather than the tumor metastatic, In the future, this information could allow doctors to make better decisions about managing the disease. cancer of a patient.

Researchers studied several samples of circulating tumor DNA collected over time to understand how cancer of a patient in response to treatment.

He focused on inhibitors of the androgen receptor pathway. He found that the current treatment for cancer Prostate metastatic actively change the composition of the population of cancer in the body and that treatment often selects a population of cancer Biologically aggressive drugs that reduce clinical resistance.

This allowed them to identify new genetic mechanisms of resistance to the most common treatments. cancer Prostate metastatic, The technique can be applied to other types as well. cancer,

The research team used nucleosome fingerprints in circulating tumor DNA to estimate messenger ribonucleic acid (mRNA) expression in synchronously biopsied metastases. They identified treatment-induced changes in androgen receptor transcription factor signaling activity.

This means that whole genome sequencing of circulating tumor DNA can reveal active processes occurring within cells, allowing clinicians to predict which treatments will be effective or ineffective in each patient.

“The breadth of information about our research has increased significantly cancer can be obtained from a few drops of sangre”, Dr. Wyatt said. “From a clinical perspective, this additional information could be used in new clinical trials that are testing strategies to target treatment cancer Only those whose quality or length of life will improve.

clinical trials

Whole genome circulating tumor DNA sequencing technology, which is minimally invasive, inexpensive and scalable, is now being applied in larger clinical trials to help uncover new mechanisms of treatment resistance, the study authors wrote. Is.

The technology can also be applied to existing commercial circulating tumor DNA testing platforms, meaning that patients They may soon benefit directly from more extensive liquid biopsy tests. The research team has made the methods and computer code available to the public free of charge, so that the technology can be applied to other types of computers. cancer and clinical settings.

“Understanding how clonal evolution occurs and what drives it is one of the key questions that needs to be addressed in almost all malignancies, and this study provides that level of insight cancer prostate cancer, as well as a model and tool on how to make this work,” said Christopher Muller, MD, PhD, a biologist and geneticist cancer Professor of Biomedical and Molecular Sciences at Queen’s Cancer Research Institute and at Queen’s University.

Source consulted here.

Leave a Reply